• Luz Angela Chocontá-Piraquive, Nelson Alvis Guzmán, and Fernando De la Hoz Restrepo.
• Grupo de Epidemiología y Evaluación en Salud Pública, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C., Colombia. lachocontap@unal.edu.co
• Rev. Panam. Salud Publica. 2012 Jun 1; 31 (6): 447-53.

ObjectiveEstimating the cost-effectiveness ratio of vaccinating pregnant women against the 2009 pandemic influenza A (H1N1) in Colombia during the second wave of the pandemic.MethodsA decision tree was constructed, which simulated the health results (deaths and years of potential life lost [YPLL]) in two cohorts of pregnant women; one vaccinated, the other unvaccinated. The model's parameters were drawn from scientific literature and costs were estimated on the basis of a previous study. Incremental cost-effectiveness ratios (ICER) were calculated.ResultsVaccinating pregnant women against pandemic flu would have prevented between 4 664 and 15 741 outpatient visits and between 119 and 401 hospitalizations. Between US$ 249 530 and US$ 842 163 in costs of care would have been avoided. For the base scenario, vaccinating pregnant women would be cost-effective (ICER/YPLL avoided US$ 7 657). This ICER was responsive to the disease's fatality rate; vaccination would not be cost-effective in Colombia in scenarios with a lower fatality rate.ConclusionsVaccinating pregnant women against pandemic influenza is cost-effective in a scenario with a high mortality rate. The existing evidence that pregnant women are at increased risk of complications and that the vaccine is safe would justify its use in pregnant women.

22 keywords...

hide…